December burns update stated "The study is on-going, with target patient enrolment/treatment expected early 2022,allowing full data-set reporting to follow."
seems to indicate they expected all 30 participants to be enrolled/treated early 2022? It is now may and that update from gitmo seemed to indicate they are a long way from target. I would think early 22 would be before mid year?
It is frustrating as it just plays into the hands of shorters again, I think Rce unfortunately have very little say in the burns trial since it seems it was proposed and funded by others? It is a shame as after the initial results I had thought burns or any other surface treatment might become a fast track way to approval of a product and income generation. Now it seems burns hospital are only using it as last resort on burns that do not respond to standard care? I wonder if they had a number of acute/ chronic untreatable cases initially that prompted the trial and all were treated successfully, so now no new patients until new chronic cases appear?
- Forums
- ASX - By Stock
- RCE
- Recce Pharmaceuticals (ASX:RCE): A multi-billion-dollar sepsis solution?
Recce Pharmaceuticals (ASX:RCE): A multi-billion-dollar sepsis solution?, page-11
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
|
|||||
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $100.9M |
Open | High | Low | Value | Volume |
46.5¢ | 46.5¢ | 46.5¢ | $5.673K | 12.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
47.0¢ | 18313 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 0.475 |
1 | 10700 | 0.465 |
1 | 10000 | 0.460 |
6 | 154303 | 0.455 |
11 | 209394 | 0.450 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 1396 | 1 |
0.460 | 10800 | 2 |
0.465 | 3951 | 2 |
0.475 | 78663 | 3 |
0.480 | 130896 | 4 |
Last trade - 10.06am 16/07/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online